Numerous studies have shown overexpression of FASN in human epithelial ovarian cancer (EOC) [5]–[8] and cancers of breast [9], prostate [10], colon [11], lung [12], endometrium [13] and papillary thyroid [14]. Here, FASN is linked to ovarian carcinoma.